Timing vaccination against SARS-CoV-2
Cell Res
.
2021 Nov;31(11):1146-1147.
doi: 10.1038/s41422-021-00559-w.
Authors
Coline Barnoud
1
,
Chen Wang
1
,
Christoph Scheiermann
2
3
Affiliations
1
Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
2
Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
[email protected]
.
3
Walter-Brendel-Centre of Experimental Medicine, BioMedical Centre, Ludwig-Maximilians-University München, Planegg-Martinsried, München, Germany.
[email protected]
.
PMID:
34471238
PMCID:
PMC8408358
DOI:
10.1038/s41422-021-00559-w
No abstract available
Publication types
Research Support, Non-U.S. Gov't
Comment
MeSH terms
COVID-19*
Humans
SARS-CoV-2*
Vaccination
Grants and funding
101001233/EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council)
310030_182417/1/Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation)
20A019/Novartis Foundation
ERC_/European Research Council/International